XOMA’s (XOMA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $74.00 price target on the biotechnology company’s stock.

Separately, SVB Leerink assumed coverage on shares of XOMA in a report on Monday, April 29th. They set an outperform rating and a $40.00 price target on the stock.

XOMA Price Performance

Shares of XOMA opened at $24.78 on Wednesday. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. The stock has a market cap of $288.44 million, a PE ratio of -6.13 and a beta of 0.57. XOMA has a 12-month low of $13.48 and a 12-month high of $27.00. The business has a 50-day simple moving average of $25.13 and a two-hundred day simple moving average of $20.79.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The firm had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.01 million. Analysts anticipate that XOMA will post -2.11 earnings per share for the current fiscal year.

Institutional Trading of XOMA

An institutional investor recently raised its position in XOMA stock. BNP Paribas Financial Markets raised its position in XOMA Co. (NASDAQ:XOMA) by 55.6% during the first quarter, according to its most recent filing with the SEC. The firm owned 3,543 shares of the biotechnology company’s stock after purchasing an additional 1,266 shares during the period. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.